Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Esperion Therapeutics has entered into an agreement with TransGenRx, a provider of transgenic technology, according to which TransGenRx will produce protein-based therapeutics to be used in Esperion's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
Subscribe to our email newsletter
Esperion Therapeutics is a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases.
Under the terms of the agreement, TransGenRx is expected to coordinate production of protein-based therapies for a range of research needs using a proprietary expression system.
Researchers of Esperion are working to develop new therapies to treat cardio-metabolic disease including therapies based on HDL, the body’s ‘good’ cholesterol, which has been shown to play an important role in lipid management.
Esperion’s development platform includes therapies designed to mimic or enhance the function of HDL in managing and removing cholesterol and other lipids from atherosclerotic plaques. Researchers at Esperion have initiated preclinical and clinical research related to a variety of pathways for better lipid regulation to treat cardio-metabolic diseases, from early risk factors to acute coronary syndromes and atherosclerosis.
Esperion stated that it is working with Cleveland Clinic working to advance research involving HDL mimetics and other protein-based therapies to treat cardiovascular disease, under the collaborative research agreement with the Cleveland Clinic Foundation, on June 14, 2010.
Roger Newton, president and CEO of Esperion, said: “While HDL continues to show great promise in the treatment of cardiovascular disease, there have been challenges in the development of protein-based drug therapies. This collaboration represents an advantage in our efforts to identify and access complex protein-based therapies.”
Richard Cooper, executive vice president and chief scientific officer of TransGenRx, said: “In terms of both cost and complexity, the development of protein-based therapies requires expertise and targeted, advanced technology to be successful.
“At TransGenRx, our proprietary protein expression technology is suited to meet the key challenges in the production of therapeutic proteins, and we look forward to supporting the work by the teams at Esperion and Cleveland Clinic in efforts to develop new HDL therapies.”